MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fonc.2025.1689519

Медицинская библиотека · Frontiers in oncology · 2025

Cutaneous adverse events associated with the efficacy and benefit of immune checkpoint inhibitors: a systematic review and meta-analysis.

Zhang Li, Gao Yunge

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

Cutaneous immune-related adverse events (cirAEs) are associated with improved survival in tumor patients undergoing immune checkpoint inhibitors (ICIs) therapy, while inconsistent evidence has been reported across tumor subtypes. This study aimed to evaluate the association of cirAEs and their subtypes with cancer prognosis.

DESIGN

Systematic review and meta-analysis.

METHODS

Four databases including Cochrane Library, Embase, PubMed and Web of Science were searched for original publications from inception to April 30, 2024. A meta-analysis was carried out for overall survival (OS) and progression-free survival (PFS) of patients, and pooled hazard ratios (HRs) with 95% confidential intervals (CIs) were calculated. Subgroup analyses involving cirAEs subtype, cancer type, ICIs type, geographic region of patients, and study quality were performed.

RESULTS

Forty-five studies comprising a total of 26817 patients with ICIs treatment were included in the study. The occurrence of cirAEs was associated with prolonged OS (HR, 0.54 [95%CI, 0.46-0.63]; P < 0.001) and PFS (HR, 0.51 [95%CI, 0.43-0.60]; P < 0.001). Favorable survival was observed in patients with vitiligo, with the most pronounced OS (HR, 0.23 [95%CI, 0.18-0.33]; P < 0.001) and PFS (HR, 0.28 [95%CI, 0.21-0.38]; P < 0.001). Similarly, the prolonged OS (HR, 0.69 [95%CI, 0.64-0.74]; P < 0.001) and PFS (HR, 0.69 [95%CI, 0.58-0.82]; P < 0.001) in patients with rash. Significant benefit in OS were also observed in drug hypersensitivity or eruption, eczematous, lichenoid or lichen planus-like lesion, pruritus and psoriasis, but not in bullous pemphigoid, maculopapular and mucositis. Favorable survival was observed in patients with RCC, NSCLC and MM, with the most pronounced OS (HR, 0.22 [95%CI, 0.08-0.59]; P = 0.002) and PFS (HR, 0.22 [95%CI, 0.11-0.43]; P < 0.001) for RCC patients; and only OS benefit in HNSCC (HR, 0.64 [95%CI, 0.42-0.99]; P = 0.04). Subgroup analyses involving geographic region and study quality showed consistent results with the overall estimate confirming robustness.

CONCLUSIONS

The occurrence of cirAEs, especially in vitiligo and rash, predicted a significant survival benefits among tumor patients receiving ICIs therapy, especially in MM, RCC and NSCLC.

Для цитирования: Zhang Li, Gao Yunge. Cutaneous adverse events associated with the efficacy and benefit of immune checkpoint inhibitors: a systematic review and meta-analysis.. Frontiers in oncology. 2025. DOI: 10.3389/fonc.2025.1689519.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.